Recent results from randomized Phase III trials in front‐line non‐small cell lung cancer (NSCLC) also suggest that high TMB may not be effective at predicting survival benefits from a combination of PD‐1 and CTLA4 inhibitors [40]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.